Papers before 2008

Professor David G Lambert, Department of Cardiovascular Sciences, University of Leicester

Marzola E, Camarda V, Batuwangala M, Lambert DG, Calo' G, Guerrini R, Trapella C, Regoli D, Tomatis R, Salvadori S. (2007) Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11). Peptides. 29(5):674-9

Barnes TA, McDonald J, Rowbotham DJ, Duarte TL and Lambert DG. (2007) Effects of receptor density on Nociceptin/OrphaninFQ peptide receptor desensitisation: studies using the ecdysone inducible expression system. Naunyn Schmiedebergs Arch Pharmacol. 376(3):217-25.

Williams JP, Thompson JP, McDonald J, Barnes TA, Cote T, Rowbotham DJ and Lambert DG. (2007) Human peripheral blood mononuclear cells express nociceptin/orphanin FQ, but not mu, delta, or kappa opioid receptors. Anesth Analg. 105(4):998-1005.

Brookes ZL, Stedman EN, Guerrini R, Lawton BK, Calo G and Lambert DG. (2007) Proinflammatory and vasodilator effects of nociceptin/orphanin FQ in the rat mesenteric microcirculation are mediated by histamine. Am J Physiol Heart Circ Physiol. 293(5):H2977-85.

Kitayama M, McDonald J, Barnes TA, Calo G, Guerrini R, Rowbotham DJ and Lambert DG. (2007) In vitro pharmacological characterisation of a novel cyclic nociceptin/orphanin FQ analogue c[Cys(7,10)]N/OFQ(1-13)NH (2). Naunyn Schmiedebergs Arch Pharmacol. 375:369-376.

Cembala TM, Forde SC, Appadu BL and Lambert DG. (2007) Allosteric interaction of the neuromuscular blockers vecuronium and pancuronium with recombinant human muscarinic M2 receptors. Eur J Pharmacol. May 22; [Epub ahead of print].

Arudin M, Spagnolo B, Calo G, Guerrini R, Carra G, Fischetti C, Trapella C, Marzola E, McDonald J, Lambert DG, Regoli D and Salvadori S. (2007) Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with Calpha,alpha-dialkylated amino acids. Bioorg Med Chem. 15:4434-4443.

Lam PM, Hainsworth AH, Smith GD, Owen DE, Davies J and Lambert DG. (2007) Activation of recombinant human TRPV1 receptors expressed in SH-SY5Y human neuroblastoma cells increases [Ca2+]i, initiates neurotransmitter release and promotes delayed cell death. J Neurochem. 102:801-811.

Spagnolo B, Carra G, Fantin M, Fischetti C, Hebbes C, McDonald J, Barnes TA, Rizzi A, Trapella C, Fabton G, Morari M, Lambert DG, Regoli D and Calo G. (2007) Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies. J Pharmacol Exp Ther. 321:961-967.

Gold SJ, Thompson JP, Williams JP, Helm EE, Sadler J, Song W, Ng LL and Lambert DG (2007) Does cigarette smoking increase plasma urotensin II concentrations? Eur J Clin Pharmacol. 63:253-257.

Hainsworth AH, Nelson RM, Lambert DG, Green AR and Webb TE (2006) Glutamate receptor-mediated inhibition of L-glutamate efflux from cerebral cortex in vitro. Brain Res. 1114:36-40.

Vergura R, Valenti E, Hebbes CP, Gavioli EC, Spagnolo B, McDonald J, Lambert DG, Balboni G, Salvadori S, Regoli D and Calo G (2006) Dmt-Tic-NH-CH2-Bid (UFP-502), a potent DOP receptor agonist: in vitro and in vivo studies. Peptides. 27:3322-3330.

Behm DJ, Stankus G, Doe CP, Willette RN, Sarau HM, Foley JJ, Schmidt JJ, Nuthulaganti P, Fornwald JA, Ames RS, Lambert DG, Calo G, Camarda V, Aiyar NV and Douglas SA (2006). The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems. British Journal of Pharmacology. 148:173-190.

Song W, McDonald J, Camarda V, Calo G, Guerrini R, Marzola E, Thompson J, Rowbotham DJ and Lambert DG (2006). Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity. Naunyn-Schmiedebergs Arch. Pharmacol. 373:148-157.

Camarda V, Spagnol M, Song W, Vergura R, Roth A, Cavanni P, Guerrini R, Marzola E, Savadori S, Regoli D, Douglas SA, Thompson JP, Rowbotham DJ, Lambert DG and Calo G. (2006). In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803). British Journal of Pharmacology. 147:92-100.

Trapella C, Guerrini R, Piccagli L, Calo G, Carra G, Spagnolo B, Rubini S, Fanton G, Hebbes C, McDonald J, Lambert DG, Regoli D and Salvadori S (2006) Identification of an achiral analogue of J-113397 as potent Nociceptin/Orphanin FQ receptor antagonist. Bioorg.Med. Chem 14:692-704.

Cowley E, Thompson JP, Sharpe P, Waugh J, Ali N and Lambert DG (2005) Effects of pre-eclampsia on maternal plasma, cerebrospinal fluid and umbilical cord Urotensin II concentrations: a pilot study. Br. J. Anaes 95:495-499.

Guerrini R, Calo' G, Lambert DG, Carra G, Arduin M, Barnes TA, McDonald J, Rizzi D, Trapella C, Marzola E, Rowbotham DJ, Regoli D, and Salvadori S (2005) N- and C-Terminal Modifications of Nociceptin / Orphanin FQ Generate Highly Potent NOP Receptor Ligands. J. Med. Chem 48(5):1421-1427.

Lam PMW, McDonald J and Lambert DG (2005) Characterisation and comparison of recombinant human and rat TRPV1 receptors. Effects of exo- and endocannabinoids. Brit. J. Anaes 94:649-656.

Carra' G, Rizzi A, Guerrini R, Barnes TA, Mc Donald J, Hebbes CP, Mela F, Kenigs VA, Marzola G, Rizzi D, Gavioli E, Zucchini S, Regoli D, Morari M, Salvadori S, Rowbotham DJ, Lambert DG, Kapusta DR and  Calo G (2005) [(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor. J Pharmacol Exp Ther. 312(3):1114-1123.

Camarda V, Song W, Marzola E, Spagnol, M, Guerrini R, Salvadori S, Regoli D, Thompson JP, Rowbotham DJ, Behm DJ, Douglas SA, Calo G and Lambert DG (2004) Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. Eur. J. Pharmacol. 498:83-86.

Johnson EE, McDonald J, Nicol B, Guerrini R and Lambert DG (2004) Functional coupling of the nociceptin/orphanin FQ receptor in dog brain membranes. Brain Research 1003:18-25.

Share this page: